We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 28, 2023

Temporary Treatment Cessation vs Continuation of First-Line TKIs in Patients With Advanced Clear Cell RCC

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial
Lancet Oncol 2023 Feb 13;[EPub Ahead of Print], JE Brown, KL Royle, W Gregory, C Ralph, A Maraveyas, O Din, T Eisen, P Nathan, T Powles, R Griffiths, R Jones, N Vasudev, M Wheater, A Hamid, T Waddell, R McMenemin, P Patel, J Larkin, G Faust, A Martin, J Swain, J Bestall, C McCabe, D Meads, V Goh, T Min Wah, J Brown, J Hewison, P Selby, F Collinson

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.

Further Reading